This is an aggregated industry headline. Read the full story at Endpoints News →
Analysts focus on three programs in big year for Bristol Myers
Wall Street’s expectations for Bristol Myers Squibb’s upcoming slate of data readouts are reaching a fever pitch. Analysts lobbed questions regarding at least half a dozen trial results expected by the end of 2026, in ...
By Endpoints News
· Apr 30, 2026
· via Endpoints News
Image: Endpoints News
RxInsider combines reported facts with industry analysis and informed inference. Forward-looking reads, market commentary, and interpretive framing reflect analysis of available reporting and known facts, not confirmed outcomes.
Tags
moneyformat:headlineheadlineEndpoints News
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.
More from Money
All Money →
MoneyBioPharma Dive ↗
Research Alliance III follows a few months after Cormorant Asset Management priced a $150 million IPO for its …
MoneyFierceBiotech ↗
If any proof was needed that big money is still available for AI drug development, look no further than the 10…
MoneyFiercePharma ↗
CSL has slashed its revenue projection for the fiscal year from $15.8 billion to $15.2 billion, in another ind…